Investigational drug · Phase 2
SL-28
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SL-28"
First trial start
2026
Aug 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SL-28", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head & Neck Cancer
- Pancreas Carcinoma
- Pancreas Cancer, Metastatic
- Lung Adenocarcinoma
- Lung Cancer (NSCLC)
- Lung Cancer (Non-Small Cell)
- Esophageal Cancer
- Stomach (Gastric) Cancer
- Liver Cancer
- Intestinal Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SL-28" as an intervention, largest first.
- SL-28 for Advanced Solid TumoursRecruiting
Second Life TherapeuticsIndustry
NCT07341737 · 60 participants (planned) · Start Aug 14, 2026 · Primary completion Jan 1, 2027
Drug: SL-28; SL-28 and 1 more · For: Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic and 15 more
Sites: Sydney, Australia; Gold Coast, Australia; Adelaide, Australia
Second Life TherapeuticsIndustry
NCT06872489
Drug: SL-28. · For: Neuroblastoma in Children; Neuroblastoma, Recurrent, Refractory; Advanced Cancer and 7 more
Newest research
PubMed records naming it or its code names, newest first.
- Partial response in a patient with skeletal and hepatic metastases following resected pancreatic cancer to the novel cell therapy SL-28: a case report.
Tetz V, Kardava K, Shulenbayev O, et al. · Front Oncol 2025
- Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient with Prostate Cancer and Bone Metastasis: A Case Report.
Tetz V, Kardava K, Shulenbayev O, et al. · Immunotargets Ther 2025
- Retrospective analysis of time-related three-dimensional iliac bone graft resorption following sinus lift and vertical augmentation in the maxilla.
Steller D, Falougy M, Mirzaei P, et al. · Int J Oral Maxillofac Surg 2022
- Latarjet After Failed Arthroscopic Bankart Repair Results in Twice the Rate of Recurrent Instability Compared With Primary Latarjet.
Rodkey DL, Colantonio DF, LeClere LE, et al. · Arthroscopy 2021
- Data set for diet specific differential gene expression analysis in three Spodoptera moths.
Roy A, Walker WB, Vogel H, et al. · Data Brief 2016
- Aphanius marassantensis, a new toothcarp from the Kzlrmak drainage in northern Anatolia (Cyprinodontiformes: Cyprinodontidae).
Pfleiderer SJ, Geiger MF, Herder F · Zootaxa 2014
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.